All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retifanlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: INCMGA00012
Highest Development Status: Phase III Product Type: Large molecule
Recipient: MacroGenics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2020
Details:
MacroGenics and Incyte have each established multiple development programs for retifanlimab, evaluating the anti-PD-1 molecule either as monotherapy or in combination with other agents.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Olumiant
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The EUA is based on data from the ACTT-2, a randomized double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib in combination with remdesivir vs placebo with remdesivir in hospitalized patients with or without oxygen requirements.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MCLA-145
Therapeutic Area: Oncology Product Name: MCLA-145
Highest Development Status: Phase I Product Type: Large molecule
Recipient: MERUS LABS INTERNATIONAL INC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
MCLA-145 is currently being evaluated in a Phase 1 open-label, multicenter dose escalation study, including a safety dose expansion phase, in patients with solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: Approved Product Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020
Details:
New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ruxolitinib
Therapeutic Area: Dermatology Product Name: Jakafi
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch. Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pemigatinib
Therapeutic Area: Oncology Product Name: Pemazyre
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The New Drug Submission is based on data from the FIGHT-202 study evaluating pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Olumiant
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir. 35% decrease in death rate through Day 29 was observed in patients treated with baricitinib plus remdesivir.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retifanlimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: INCMGA00012
Highest Development Status: Phase III Product Type: Large molecule
Recipient: MacroGenics
Deal Size: $735.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020
Details:
The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous non-small cell lung cancer (NSCLC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
If approved, baricitinib would become the first JAK inhibitor indicated to help treat patients with AD. The positive opinion was based on Phase 3 BREEZE-AD clinical development program evaluating the baricitinib potential to treat AD including BREEZE-AD1 and BREEZE-AD2.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
